The value of cyclooxygenase-2 expression in differentiating between early melanomas and histopathologically difficult types of benign human skin lesions

Melanoma Research

Volumn 22, Issue 1, 2012, Pages 70-76

  Kuźbicki, Łukasz ^a   Lange, Dariusz ^b   Straczyńska Niemiec, Anita ^b   Chwirot, Barbara W ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

cutaneous melanoma; cyclooxygenase 2; marker

Indexed keywords

CYCLOOXYGENASE 2; FORMALDEHYDE; PARAFFIN;

AREA UNDER THE CURVE; ARTICLE; CELL FRACTIONATION; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DYSPLASTIC NEVUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JUVENILE MELANOMA; LENTIGO; MELANOCYTIC NEVUS; MELANOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TUMOR DIFFERENTIATION;

CYCLOOXYGENASE 2; DIAGNOSIS, DIFFERENTIAL; EARLY DETECTION OF CANCER; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; NEVUS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84855813673     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32834defec     Document Type: Article

References (29)

1. Hö lzle E, Kind P, Plewig G, Burgdorf W. Malignant melanoma diagnosis and differential diagnosis. New York: Schattauer; 1993.
2. Ng JC, Swain S, Dowling JP, Wolfe R, Simpson P, Kelly JW. The impact of partial biopsy on histopathologic diagnosis of cutaneous melanoma: experience of an Australian tertiary referral service. Arch Dermatol 2010; 146:234-239.
3. Barnhill RL, Busam KJ. Pathology of melanocytic nevi and malignant melanoma. Boston: Butterworth-Heinemann; 1995.
4. MooiWJ. Cutaneous melanocytic nevus versus melanoma: pitfalls, surprises, dilemmas. Eur J Surg Oncol 1999; 25:622-627.
5. McCarthy SW, Scolyer RA. Melanocytic lesions of the face: diagnostic pitfalls. Ann Acad Med Singapore 2004; 33:3-14.
6. Cook MG. Benign melanocytic lesions mimicking melanomas. Pathology 2004; 36:414-418. (Pubitemid 39273984)
7. Strungs I. Common and uncommon variants of melanocytic naevi. Pathology 2004; 36:396-403. (Pubitemid 39273982)
8. Lee JB. Spitz nevus versus melanoma: limitation of the diagnostic methodology exposed. Eur J Dermatol 2006; 16:223-224. (Pubitemid 43736138)
9. Ko CJ, McNiff JM, Glusac EJ. Melanocytic nevi with features of Spitz nevi and Clark's/dysplastic nevi ('Spark's' nevi). J Cutan Pathol 2009; 36:1063-1068.
10. Farmer ER, Gonin R, Hanna MP. Discordance in the histopathologic diagnosis of melanoma and melanocytic nevi between expert pathologists. Hum Pathol 1996; 27:528-531. (Pubitemid 26187274)
11. Cook MG, Clarke TJ, Humphreys S, Fletcher A, McLaren KM, Smith NP, et al. The evaluation of diagnostic and prognostic criteria and the terminology of thin cutaneous malignant melanoma by the CRC Melanoma Pathology Panel. Histopathology 1996; 28:497-512. (Pubitemid 26192946)
12. Brochez L, Verhaeghe E, Grosshans E, Haneke E, Pié rard G, Ruiter D, et al. Inter-observer variation in the histopathological diagnosis of clinically suspicious pigmented skin lesions. J Pathol 2002; 196:459-466 (Pubitemid 34262859)
13. Lodha S, Saggar S, Celebi JT, Silvers DN. Discordance in the histopathologic diagnosis of difficult melanocytic neoplasms in the clinical setting. J Cutan Pathol 2008; 35:349-352. (Pubitemid 351363772)
14. Shoo BA, Sagebiel RW, Kashani-Sabet M. Discordance in the histopathologic diagnosis of melanoma at a melanoma referral center. J Am Acad Dermatol 2010; 62:751-756.
15. Slingluff CL, Vollmer RT, Reintgen DS, Seigler HF. Lethal 'thin' malignant melanoma. Identifying patients at risk. Ann Surg 1988; 208:150-161.
16. de Wit NJ, van Muijen GN, Ruiter DJ. Immunohistochemistry in melanocytic proliferative lesions. Histopathology 2004; 44:517-541. (Pubitemid 38845098)
17. Gould Rothberg BE, Rimm DL. Biomarkers: the useful and the not so useful - an assessment of molecular prognostic markers for cutaneous melanoma. J Invest Dermatol 2010; 130:1971-1987.
18. Kuźbicki L, Sarnecka A, Chwirot BW. Expression of cyclooxygenase-2 in benign naevi and during human cutaneous melanoma progression. Melanoma Res 2006; 16:29-36. (Pubitemid 44133048)
19. Chwirot BW, Kuźbicki L. Cyclooxygenase-2 (COX-2): first immunohistochemical marker distinguishing early cutaneous melanomas from benign melanocytic skin tumours. Melanoma Res 2007; 17:139-145. (Pubitemid 46788098)
20. Vogt T, McClelland M, Jung B, Popova S, Bogenrieder T, Becker B, et al. Progression and NSAID-induced apoptosis in malignant melanomas are independent of cyclooxygenase II. Melanoma Res 2001; 11:587-599. (Pubitemid 33152350)
21. Goulet AC, Einsphar JG, Alberts DS, Beas A, Burk C, Bhattacharyya A, et al. Analysis of cyclooxygenase 2 (COX-2) expression during malignant melanoma progression. Cancer Biol Ther 2003; 2:713-718.
22. Denkert C, Kö bel M, Berger S, Siegert A, Leclere A, Trefzer U, et al. Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res 2001; 61:303-308. (Pubitemid 32095731)
23. Bianchini F, Massi D, Marconi C, Franchi A, Baroni G, Santucci M, et al. Expression of cyclooxygenase-2 in macrophages associated with cutaneous melanoma at different stages of progression. Prostaglandins Other Lipid Mediat 2007; 83:320-328. (Pubitemid 46710469)
24. Meyer S, Vogt T, Landthaler M, Berand A, Reichle A, Bataille F, et al. Cyclooxygenase 2 (COX2) and peroxisome proliferator-activated receptor gamma (PPARG) are stage-dependent prognostic markers of malignant melanoma. PPAR Res 2009; 2009:848645.
25. Lee C, Ramirez JA, Guitart J, Diaz LK. Expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma during malignant melanoma progression. J Cutan Pathol 2008; 35:989-994.
26. Becker MR, Siegelin MD, Rompel R, Enk AH, Gaiser T. COX-2 expression in malignant melanoma: a novel prognostic marker? Melanoma Res 2009; 19:8-16.
27. Minami S, Lum CA, Kitagawa KM, Namiki TS. Immunohistochemical expression of cyclooxygenase-2 in melanocytic skin lesions. Int J Dermatol 2011; 50:24-29.
28. Figueiredo A, Caissie AL, Callejo SA, McLean IW, Gold P, Burnier MN Jr. Cyclooxygenase-2 expression in uveal melanoma: novel classification of mixed-cell-type tumours. Can J Ophthalmol 2003; 38:352-356. (Pubitemid 37295119)
29. Kuźbicki L, Lange D, Chwirot BW. Cyclooxygenase-2 immunohistochemistry in human melanoma: differences between results obtained with different antibodies. Melanoma Res 2009; 19:294-300.